For research use only. Tirzepatide is not approved by the FDA for use in this research chemical context and is sold by Iron Labs exclusively for laboratory research. Not for human consumption.
Tirzepatide: A Dual-Agonist Research Tool
Tirzepatide is a synthetic 39-amino acid peptide that functions as a dual agonist at both the GLP-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Developed initially by Eli Lilly, it represents a structurally novel class of dual incretin receptor agonist distinguished from single-pathway GLP-1 agonists like Semaglutide by its simultaneous activation of two complementary metabolic signaling pathways. For research purposes, this dual mechanism makes Tirzepatide a valuable tool for studying the additive and synergistic effects of GLP-1R and GIPR co-stimulation.
Dual Receptor Mechanism Under Study
The pharmacological profile of Tirzepatide is defined by its balanced agonism at both GLP-1R and GIPR. Research examining this dual mechanism has focused on:
- GLP-1R signaling: Like Semaglutide, Tirzepatide activates GLP-1R to stimulate cAMP production in pancreatic beta cells, enhance glucose-dependent insulin secretion, and suppress glucagon release. It also engages central GLP-1R in appetite-regulating brain regions.
- GIPR signaling: GIPR activation by Tirzepatide adds a distinct layer of incretin signaling. GIP receptors are expressed in adipose tissue, bone, and brain regions. Research has examined how GIPR agonism at adipocytes influences lipid storage, fatty acid re-esterification, and energy partitioning in animal models.
- Adipose tissue biology: A key area of Tirzepatide research involves its distinct effects on fat tissue compared to GLP-1-only agonists. Animal studies have examined Tirzepatide’s influence on subcutaneous vs. visceral fat depots, adipocyte differentiation, and insulin sensitivity in adipose tissue.
- Hepatic metabolism: Preclinical research has examined Tirzepatide in models of non-alcoholic fatty liver disease (NAFLD), looking at hepatic lipid accumulation, fibrosis markers, and gluconeogenesis regulation.
- Energy expenditure: Compared to GLP-1-only agonists, Tirzepatide research has noted superior energy expenditure effects in animal models, with studies examining brown adipose tissue thermogenesis and mitochondrial uncoupling protein expression.
Tirzepatide vs. Semaglutide: Key Research Differences
| Parameter | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor targets | GLP-1R + GIPR | GLP-1R only |
| Half-life | ~5 days | ~7 days |
| Adipose tissue effects | Direct GIPR action on fat cells | Indirect via central mechanisms |
| Beta-cell mechanism | Dual incretin pathway | GLP-1 pathway only |
| Energy expenditure models | Greater in animal studies | Significant but lower comparatively |
Laboratory Handling
Tirzepatide is supplied as lyophilized powder. Reconstitute with bacteriostatic water. Store lyophilized stock at -20°C away from light; reconstituted solution at 2–8°C for up to 21–28 days. Handle with sterile technique. Tirzepatide’s fatty acid conjugation makes it sensitive to repeated freeze-thaw cycles.
Source Tirzepatide for your research → Iron Labs Research Catalog
Regulatory Notice
Tirzepatide sold by Iron Labs is a research chemical for laboratory use only. Not approved by the FDA for human therapeutic use in this context. Iron Labs makes no health, metabolic, or weight-related claims. For research purposes only.